CORXEL’s Varenicline Nasal Spray Approved by NMPA for Dry Eye Treatment
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has received approval...
Drug
Pfizer Partners with CR Pharma to Expand Cancer Drug Access in China
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has entered into a strategic agreement with China...
CanSino Biologics’ Menhycia Vaccine Aims to Expand Age Range with NMPA Filing
CanSino Biologics (HKG: 6185) has announced that the National Medical Products Administration (NMPA) has accepted...
Jiangsu Hengrui Medicine’s SHR-1819 Receives NMPA Approval for Atopic Dermatitis Clinical Trial
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received clinical trial...
AstraZeneca’s Truqap Meets Primary Endpoint in Phase III Prostate Cancer Study
UK-based pharmaceutical giant AstraZeneca Inc., (AZ, NASDAQ: AZN) has announced that its Phase III CAPItello-281...
Sichuan Huiyu Pharmaceutical’s HY-2003 Approved for Clinical Trials by China’s NMPA
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...
J&J’s Stelara Faces New Biosimilar Competition in China with CSPC Pharmaceutical’s Entry
Johnson & Johnson (J&J, NYSE: JNJ)’s auto-immune disease drug Stelara (ustekinumab) is set to encounter...
Amgen’s MariTide Showcases Significant Weight Loss in Phase II Study
US biotechnology company Amgen (NASDAQ: AMGN) has announced positive outcomes from the double-blind, dose-ranging Phase...
Roche’s SKYSCRAPER-01 Study: Tiragolumab-Tecentriq Combo Misses Primary Endpoint in NSCLC
Swiss pharmaceutical giant Roche (SWX: ROG) has reported an update on the phase III SKYSCRAPER-01...
Merck’s Winrevair Shows Positive Results in Phase III ZENITH Study for PAH
US-based pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced positive interim analysis results...
Nasal-Phyto Pharmaceutical Receives FDA Clearance for First-Ever Olfactory Drug-Device Combo
China-based Nasal-Phyto Pharmaceutical Technology Group Co., Ltd has announced receiving clinical clearance from the US...
GSK’s Blenrep BLA for Multiple Myeloma Treatments Accepted by FDA for Review
UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) has announced that the US Food and Drug...
Insilico Medicine Gets FDA Approval for Clinical Study of ENPP1 Inhibitor ISM5939
China’s generative artificial intelligence (AI)-driven biotech company, Insilico Medicine, has announced that it has received...
SCG Cell Therapy Presents Phase I Data for HBV-Specific TCR-T Therapy SCG101 at AASLD 2024
SCG Cell Therapy Pte. Ltd, a Singapore-based company with a presence in Shanghai, has announced...
Shenzhen Kangtai Begins Phase I Clinical Trial for 20-Valent Pneumococcal Vaccine
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the enrollment of the...
Sichuan Kelun-Biotech Receives NMPA Clearance for SKB501 Clinical Trial in Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received clearance from...
Lepu Medical Technology Gains NMPA Approval for Obesity and Diabetes Treatments MWN109 and MWN105
China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease...
Merck’s Winrevair Shows Positive Results in Phase III ZENITH Study for PAH
US-based pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced favorable interim analysis results...
GeneQuantum Healthcare’s GQ1011 (AMB302) Receives FDA Approval for Clinical Study
China-based GeneQuantum Healthcare, a leading developer of antibody drug conjugates (ADCs), has announced that it...
Henlius Biotech Initiates Phase III Study for HLX22 in Gastric Cancer Treatment
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the dosing of the first patient...